|
Accueil > Actualité
Amgen: Q1 EPS slips 1%
(CercleFinance.com) - Amgen reported Q1 2024 non-GAAP EPS that is down 1% to $3.
96 on Thursday evening, with its non-GAAP operating margin down 5.1 points to 43.2% on revenues that are up 22% to $7.4bn. The biotech group's product sales rose 25% in volumes, boosted by at least 10% growth for ten products, including Repatha, Tezspire, Evenity, Blincyto and Tavneos. Amgen now expects adjusted EPS of $19 to $20.20, with revenues of $32.5bn to $33.8bn, compared with target ranges of $18.90-$20.30 and $32.4b-$33.8bn respectively previously. Copyright (c) 2024 CercleFinance.com. All rights reserved. |
31/10/2024 16:21
KKRune facilité de crédit de 150M$ pour Birch Creek 31/10/2024 16:10 GE Vernovamise sous tension de cinq sous-stations en Irak 31/10/2024 16:00 GetlinkEiffage dépasse les 25% des votes 31/10/2024 15:53 Accentureréalise un investissement dans 1910 Genetics 31/10/2024 15:45 Nvidial'UE examine le projet d'acquisition de Run Labs 31/10/2024 15:37 Rubisplombé par une révision d'objectifs annuels Tous les articles sociétés |
